Sign in Subscribe
Cancer

Chemotherapy-Induced Anemia Market Outlook 2032: Emerging Therapies and Global Trends

Strategic Insights

— 1 min read

The Chemotherapy-Induced Anemia market in the seven major markets (7MM) is expected to witness significant growth, driven by the launch of emerging therapies and increasing incidence of Chemotherapy-Induced Anemia cases. In 2021, the market size exceeded USD 1 billion, with approximately 1.6 million incident cases reported. The market is dominated by players such as Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, and Zydus Cadila. Current treatments primarily involve erythropoiesis-stimulating agents (ESAs), but emerging therapies like roxadustat, ALRN-6924, and Desidustat offer new treatment options with potentially fewer side effects.

Key Takeaways:

  • The Chemotherapy-Induced Anemia market is projected to grow at a steady Compound Annual Growth Rate (CAGR) of 10.5% by 2032, driven by the launch of emerging therapies.
  • The total market size across the 7MM exceeded USD 1 billion in 2021, with approximately 1.6 million incident cases reported.
  • Roxadustat has received approval for the treatment of anemia associated with chronic kidney disease (CKD) in several regions, including the European Union (EU), European Economic Area (EEA) countries, Japan, China, South Korea, and Chile.
  • Emerging therapies like ALRN-6924 and Desidustat are also in development, offering new treatment options for patients.
  • The Indian Council of Medical Research (ICMR) has adopted a groundbreaking tool called AnemiaPhone, developed by a research team at Cornell, to streamline the diagnosis of iron deficiency.
  • Akums has introduced India's first locally developed hydroxyurea oral solution, aimed at treating sickle cell disease in pediatric patients.
  • Akebia Therapeutics has announced the launch of its anemia treatment Vafseo for dialysis patients and plans to collaborate with the FDA to further evaluate the drug's potential in the pre-dialysis population.

Statistics:

  • In 2021, the Chemotherapy-Induced Anemia market size across the 7MM exceeded USD 1 billion.
  • Approximately 1.6 million incident cases of Chemotherapy-Induced Anemia were reported in 2021.
  • The market is expected to grow at a CAGR of 10.5% by 2032.
  • Roxadustat has received approval in several regions, including the EU, EEA, Japan, China, South Korea, and Chile.
  • The market size is projected to reach USD 2.5 billion by 2032.

Sources:

  • M2 PressWIRE-August 19, 2025-: Chemotherapy Induced Anemia Market Outlook 2034
  • DelveInsight's report, "Chemotherapy Induced Anemia Market Insights, Epidemiology, and Market Forecast-2032"
  • "Chemotherapy Induced Anemia Market Forecast"
  • "Chemotherapy Induced Anemia Overview"
  • "Chemotherapy Induced Anemia Epidemiology"
  • "Chemotherapy Induced Anemia Therapeutics Assessment"
  • "Chemotherapy Induced Anemia Report Key Insights"

Read more